EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Clinically actionable alterations in Indian breast cancer patients derived through whole transcriptome sequencing

Nilesh Gardi, Rohan Chaubal, Khushboo A Gandhi, Anushree Kadam, Ankita Singh, Aishwarya Sabari Raja, Vaibhav Vanmali, Rohini Hawaldar, Suhani Sale, Shalaka Joshi, Rajendra Badwe, Sudeep Gupta

The Indian Journal of Medical Research · 28.02.2026 · 163 · 95-103

DOI: 10.25259/ijmr_1642_2024 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Indian Journal of Medical Research, online erschienen am 28.02.2026. Verfasst von Nilesh Gardi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinician Scientist Laboratory, Advanced Centre for Treatment, Research, and Education in Cancer, Tata Memorial Centre, Mumbai, Maharashtra, India. Hauptthemen laut MEDLINE: Breast Neoplasms, Transcriptome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives Genomic studies are essential for identifying mutations that may influence key aspects of breast tumours, such as susceptibility, aggressiveness, and response to treatment. There are deficient molecular and genomic data from Indian breast cancer patients. Methods mRNA from primary breast cancer samples were subjected to next-generation transcriptome (mRNA) sequencing on an Illumina platform, in duplicates and triplicates to generate 30–60 M reads/sample. PAM50, and absolute intrinsic molecular subtyping (AIMS) gene expression-based classifiers were used for intrinsic subtyping. Variants were called using, GATK, MuTect2, VarScan2, and VarDict, followed by filtering for somatic and non-synonymous changes. Germline variants were excluded using public databases. ClinVar annotations prioritised pathogenic variants, and the STRING algorithm was used for network analysis. Results A total of 207 RNA-Seq datasets from 97 breast cancer patients were analysed. There was good concordance between the immunohistochemical receptor and AIMS classification for all subtypes, but there was discordance between immunohistochemical and PAM50 subtypes within the ER-positive/HER2-positive subgroup, wherein only 38.5% (n= 5) were classified as HER2-like by gene expression classification. Variant analysis identified 145 high-confidence somatic mutations, with TP53 (n=46, 47%) and PIK3CA (n=33, 34%) being the most frequent. Additional actionable mutations in BRCA1 , BRCA2 , FGFR2 , PTEN , AKT1, and mTOR pathways were identified. At least one actionable mutation was found in 52% of patients. Fusion transcript analysis identified 91 recurrent fusions, including novel partners with ERBB2 , MED1 , and CDK12 , suggesting the possibility of unique molecular events. Interpretation and conclusions This study demonstrates that Indian breast cancer patients exhibit molecular subtypes and actionable mutations comparable to Caucasian cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTranscriptomeHumansFemaleClass I Phosphatidylinositol 3-KinasesIndiaMutationGene Expression Regulation, NeoplasticTumor Suppressor Protein p53Erb-b2 Receptor Tyrosine KinasesBRCA2 ProteinHigh-Throughput Nucleotide SequencingMiddle AgedReceptor, Fibroblast Growth Factor, Type 2Gene Expression ProfilingAdultProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesBiomarkers, TumorPTEN Phosphohydrolase

Stichwörter der Autor:innen

Breast cancerIntrinsic subtypePIK3CATP53Transcriptome

Substanzen

Class I Phosphatidylinositol 3-KinasesPIK3CA protein, humanTumor Suppressor Protein p53Erb-b2 Receptor Tyrosine KinasesBRCA2 ProteinReceptor, Fibroblast Growth Factor, Type 2ERBB2 protein, humanProto-Oncogene Proteins c-aktPTEN protein, humanFGFR2 protein, human

Autor:innen und Institutionen

  • Clinician Scientist Laboratory, Advanced Centre for Treatment, Research, and Education in Cancer, Tata Memorial Centre, Mumbai, Maharashtra, India.
  • Training School Complex, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Department of Surgical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Mumbai, Maharashtra, India.
  • Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Mumbai, Maharashtra, India.

Zitieren

APA

Gardi, N., Chaubal, R., Gandhi, K. A., Kadam, A., Singh, A., Raja, A. S., Vanmali, V., Hawaldar, R., Sale, S., Joshi, S., Badwe, R., & Gupta, S. (2026). Clinically actionable alterations in Indian breast cancer patients derived through whole transcriptome sequencing. The Indian Journal of Medical Research, 163, 95-103. https://doi.org/10.25259/ijmr_1642_2024

Vancouver

Gardi N, Chaubal R, Gandhi KA, Kadam A, Singh A, Raja AS, et al. Clinically actionable alterations in Indian breast cancer patients derived through whole transcriptome sequencing. The Indian Journal of Medical Research. 2026;163:95-103. doi:10.25259/ijmr_1642_2024

BibTeX
@article{Gardi2026,
  author = {Gardi, Nilesh and Chaubal, Rohan and Gandhi, Khushboo A and Kadam, Anushree and Singh, Ankita and Raja, Aishwarya Sabari and Vanmali, Vaibhav and Hawaldar, Rohini and Sale, Suhani and Joshi, Shalaka and Badwe, Rajendra and Gupta, Sudeep},
  title = {Clinically actionable alterations in Indian breast cancer patients derived through whole transcriptome sequencing},
  journal = {The Indian Journal of Medical Research},
  year = {2026},
  volume = {163},
  pages = {95--103},
  doi = {10.25259/ijmr_1642_2024}
}
Kostenlos starten →